Mayne Pharma’s recent addition, BE&K’s second project at this location, contains approximately 128,000 sf of ground floor operational space and more than 27,000 sf of mezzanine space provided for critical MEP systems. The building provides space for production, labs, associated support areas, warehousing, and plant utilities. Production areas feature clean room spaces. The new facility more than quadruples the company’s capacity to manufacture oral solid-dose pharmaceutical products in the U.S. to well over 1 billion doses annually. The facility enables Mayne Pharma to offer clients a comprehensive “concept to commercialization” solution under one FDA site registration. Special consideration was provided to reduce the risk of cross-contamination within the facility by designing specific flows of personnel, materials, and equipment.